Company
Takeda Pharmaceutical Company Limited
Headquarters: Tokyo, Japan
Founded: Doshomachi, Osaka, Japan June 12, 1781
Employees: 47,099
CEO: Mr. Christophe Weber
Market Cap
¥6.296 Trillion
JPY as of Jan. 1, 2023
US$46.57 Billion
Takeda Pharmaceutical Company Limited Categories
Japan
languages
Healthcare
languages
Drug Manufacturers—Specialty & Generic
Japan Healthcare
Japan Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
MERCK Kommanditgesellschaft auf Aktien
|
$87.64 B |
Zoetis Inc.
|
$68.38 B |
|
Eisai Co. Ltd
|
$17.23 B |
|
PPD, Inc.
|
$16.58 B |
|
Shionogi & Co. Ltd
|
$14.38 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Stocks & Indices
Takeda Pharmaceutical Company Limited has the following listings and related stock indices.
Stock: JPX: 4502
Stock: NYSE: TAK
Stock: FSX: TKDA
Stock: XSTU: TKDA
Stock: FSX: TKD
Stock: BMV: TAKN
Stock: OTC: TKPHF
Key People
Founder(s): Chobei Takeda I
Yasuchika Hasegawa (Chairman of the Board) Christophe Weber (President & CEO)
Financials
Revenue: ¥1,770,531 million (FY 2018)[* 1]
Operating income: ¥241,789 million (FY 2018)[* 1]
Net income: ¥186,886 million (FY 2012)[* 1]
Total assets: ¥4,106,463 billion (FY 2018)[* 1]
Total equity: ¥1,997,424 billion (FY 2018)[* 1]